Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.
Servizos
Servizos
Data de publicación
2014Título da revista
Arthritis and Rheumatology
Tipo de contido
Publicación de congreso
